



**Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors**

**Drug Name:** dapagliflozin, dapagliflozin/metformin, Steglatro

**Effective Date:** 12/2017

**Reviewed Date:** 07/2018, 5/2019, 9/2020, 2/2021, 6/2021, 11/2021, 5/2022, 4/2023, 3/2024, 5/2024

<p><b>Required Medical Information:</b></p>	<ul style="list-style-type: none"> <li>• The request is for dapagliflozin, Steglatro, or dapagliflozin/metformin for the treatment of diabetes; AND             <ul style="list-style-type: none"> <li>○ Patient is 18 years of age or older; AND</li> <li>○ Patient has not achieved adequate glucose control using an adequate/maximized dose and appropriate duration of metformin (2 grams/day); OR</li> </ul> </li> <li>• The request is for dapagliflozin and is being used for the treatment of heart failure (NYHA class II-IV) or being used in patients with chronic kidney disease (CKD) who are at risk of progression and will be used in conjunction with standard disease therapy</li> </ul>
<p><b>Quantity Limit:</b></p>	<ul style="list-style-type: none"> <li>• 1 tablet per day for dapagliflozin, dapagliflozin/metformin 10-1000mg, Steglatro</li> <li>• 2 tablets per day for dapagliflozin/metformin 5-1000mg</li> </ul>
<p><b>Coverage Duration:</b></p>	<ul style="list-style-type: none"> <li>• 12 months</li> </ul>
<p><b>Coding Logic for Step Therapy:</b></p>	<ul style="list-style-type: none"> <li>• Formulary dapagliflozin, dapagliflozin/metformin and Steglatro will pay if there is at least one paid claim of a 30-day supply of formulary metformin or SGLT2 within the last 365 days</li> </ul>

**Investigational use:** Neighborhood does not provide coverage for drugs when used for investigational purposes. All therapies are considered investigational when used at a dose or for a condition other than those that are recognized as medically accepted indications as defined in any one of the following standard reference compendia: American Hospital Formulary Service Drug information (AHFS-DI), Thomson Micromedex DrugDex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs, or Peer-reviewed published medical literature indicating that sufficient evidence exists to support use.